I've written more about these really useful data here for @RheumNow: https://t.co/3dQteFr9qZ #ACR21 @earlyarthritis @BykerkVivian https://t.co/7HufoWVtCK

• Can tender and swollen joint counts work in a telemedicine world? | RheumNow
• David Liew on Twitter: "In a telemedicine world where you can't palpat…

AURORA 2 (A2): SLE + LN AURORA 1: Adding Voclosporin to MMF + Steroids ⬆️complete renal response by 18% @ 52w A2: @ 30 months 💠Maintained mean GFR 💠Maintained reductions in proteinuria 💠Further safety/efficacy data to follow https://t.co/wSvQvueKi7 #ACR2021 Abst#1425 @RheumNow

• Voclosporin for Lupus Nephritis: Interim Analysis of the AURORA 2 Extension Stu…

Median survival for pts w/#VEXAS➡️10 years Predictors of mortality w/VEXAS: 👉p.MetVal mutation HR 3.5 (95%CI, 1.4-8.5) 👉transfusion dependency HR 2.59 (95%CI, 0.94-7.09) 👉⬇️risk w/ear chondritis HR 0.26 (95%CI,0.09-0.6) @marcelaferrada #ACR21 @rheumnow Abstr#1426 #ACRbest

Plenary on VEXAS - good over view of VEXAS and why important to Rheums #ACR21 Abstract# 1426 https://t.co/jx0mQNlfwK

SLE Panel: Learning about Lupus at #ACR21 Drs. Kathryn Dao ( @KDAO2011) , Janet Pope ( @Janetbirdope) Yuz Yusof ( @Yuz6Yusof) Bella Mehta ( @bella_mehta) and Pedro Castillo ( @_Castillo_Pedro) discuss lupus-related data presented Saturday. https://t.co/h0vPIwUeOz https://t.co/eJDtRKPdYT

• https://bit.ly/3o9VuzY

Clinical Pearl from Dr. @JKolfenbach "Sometimes, taking off the mask is worth it" during physical exam: ➡️Strawberry gums in GPA ➡️Drug-induced gingival hyperplasia ‣ i.e. cyclosporine, CCB ➡️Tongue necrosis in GCA ➡️Ovoidal palatal patch in TIF1gamma DM #ACR21 @RheumNow https://t.co/H98bTLLse6

Wonderful overview of myositis autoantibodies to reference from the Rheum Secrets & Pearls session by Dr. @JKolfenbach & Dr. John Stone at #ACR21 that can be accessed on-demand now! @RheumNow https://t.co/H6N02MzFSu

#ACR21 #Abstr1423 Munroe & James developed a novel #Lupus Classification Risk Immune Index using either 9 or 32 soluble mediators from sera. This index could predict transition to meeting classification criteria (with or without autoantibodies) @RheumNow https://t.co/Kr9fWaoW1L https://t.co/8wkgrzeRnt

• Ability of Soluble Immune Mediators and SLE-associated Autoantibody Specificiti…

Spanish study finds OP is more frequent in male PsA pts, assoc'd w/age independent of dz hx. Femoral OP more frequent in pts w/ axial involvement, HTN, heart ischemic disease & vitamin D deficiency. Abs 1325 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/A3v6ZHZnN8 https://t.co/2jfAOSuLtK

• Osteoporosis in Psoriatic Arthritis - ACR Meeting Abstracts

We @HSpecialSurgery previously demonstrated improved fetal mortality in #lupus in @AnnalsofIM Racial disparities persist ~61K #lupus pregnancies - 10 yr US national data #abst1034 at #ACR21 more reduction in Asians and Hispanics than African Americans @RheumNow https://t.co/KeO0FdMB7f

Abst1314 #acr21 @RheumNow factors associated w/ Acute anterior uveitis in AxSpA: -history of AAU -male gender - presence of extraspinal involvement -concomitant cs-DMARD usage -BASDAI scores ASDAS-CRP, and PGA of disease activity. https://t.co/4YA8dSJzy3

Raised BMI is related to poorer outcomes to biologics in PsA. The mean change in outcome measures (cDAPSA, RAPID3, PsAID) was lowest among obese patients . This was observed primarily among TNFi initiators vs to OSM or IL17i @RheumNow #ACR21 Abstr#1327 https://t.co/pm7PPp9UH4 https://t.co/j5GWpCBD2d

• Impact of BMI on Treatment Response Among PsA Patients Initiating TNF Inhibitor…

Real-world PsA study: MDA assoc'd w/ higher probability of achieving clinically meaningful improvements in dz activity & PROMs. MDA pts more likely w/ b/tsDMARDs, but found in less than 25% of pts in COREVITAS cohort. Abs 1344 #ACR21 #RheumNow @RheumNow https://t.co/RrAfXvn4kf https://t.co/TjPCwzYfZK

• Impact of Achieving Minimal Disease Activity on Patient-Reported Outcome Measur…

How does @US_FDA see Tyk2 inh: part of or separate to JAKi class? “I don’t think I’m in a position to make a call on this at this meeting, but certainly Tyk2 is a JAK” Tantalising end to a great session at #ACR21. Feels like the audience could have questions for days. @RheumNow

#ACR21 plenary#1424. JUNIPERA study for Secukinumab for ERA, JPsA ⭐️Time to disease flare longer in SEC vs PBO ⭐️Sustained improvement up to wk 104 ▶️Rapid decrease of JADAS-27 in initial open-label portion of study https://t.co/m5bl9Ho163 @Rheumnow https://t.co/wnEdxeYfjh

• https://bit.ly/3bPbT7t